SCHEMBL17954451

SCHEMBL17954451

CCCCC/C=C\C/C=C\CCCCCCC1(CCCCCC/C=C\CCCCCCCC)CC(=O)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.53
FAAH O00519 2/20 0.53
TRPV1 Q8NER1 1/20 0.47
PTPN1 P18031 2/20 0.46
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
F7 P08709 3/20 0.46
F3 P13726 3/20 0.46
PPARG P37231 3/20 0.46
FABP3 P05413 3/20 0.46
PPARD Q03181 2/20 0.46
PPARA Q07869 2/20 0.46
DUSP3 P51452 1/20 0.46
PTPN7 P35236 1/20 0.46
FFAR1 O14842 1/20 0.46
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP19A1 P11511 1/20 0.46
FABP4 P15090 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19390524 1.00 MGLL (0.53) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL17954446 1.00 MGLL (0.53) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL2621385 1.00 MGLL (0.53) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL10188281 0.88 MGLL (0.55) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL22448296 0.86 MGLL (0.52) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL19390731 0.84 MGLL (0.54) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL19380742 0.84 MGLL (0.54) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL10188292 0.84 MGLL (0.54) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL19380686 0.81 MGLL (0.50) MGLLFAAHTRPV1PTPN1ALDH1A1
SCHEMBL19380746 0.80 MGLL (0.49) MGLLFAAHTRPV1PTPN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160213785-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213785-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, LCAT, NPC1L1 MGLL 57/4885FAAH 686/4885TRPV1 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.